Develops gene editing therapies for hepatitis B and muscular dystrophy.
Jun 2026Revenue $45.1M/yrExpenses $81.5M/yr
No trendCash runway ≈ 1.7 years from Jun 2026
Figures by year
When will Precision Biosciences be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $45.1M and expenses $81.5M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $34.3M | $86.4M | −$52.1M |
| Dec 2024 | $68.7M | $94.9M | −$26.2M |
| Dec 2023 | $48.7M | $92.5M | −$43.7M |
| Dec 2022 | $25.1M | $87.4M | −$62.3M |
| Dec 2021 | $116M | $155M | −$39.4M |
| Dec 2020 | $24.3M | $134M | −$110M |
| Dec 2019 | $22.2M | $109M | −$87.2M |
| Dec 2018 | $10.9M | $58.8M | −$47.9M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.